

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8675902/publications.pdf>

Version: 2024-02-01

14
papers

2,949
citations

623188

14
h-index

996533

15
g-index

16
all docs

16
docs citations

16
times ranked

3776
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of hypoxia in cancer therapy by regulating the tumor microenvironment. <i>Molecular Cancer</i> , 2019, 18, 157.	7.9	1,121
2	Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 832-842.	5.1	350
3	Multiple functions of m6A RNA methylation in cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 48.	6.9	255
4	Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. <i>Molecular Cancer</i> , 2020, 19, 112.	7.9	243
5	Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts. <i>Molecular Cancer</i> , 2017, 16, 148.	7.9	216
6	Role of hypoxia-induced exosomes in tumor biology. <i>Molecular Cancer</i> , 2018, 17, 120.	7.9	211
7	Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer. <i>Molecular Cancer</i> , 2020, 19, 94.	7.9	168
8	Extracellular vesicles-mediated noncoding RNAs transfer in cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 57.	6.9	75
9	Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. <i>Molecular Therapy</i> , 2022, 30, 3133-3154.	3.7	73
10	Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling. <i>PLoS Genetics</i> , 2016, 12, e1006244.	1.5	70
11	MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression. <i>Cell Proliferation</i> , 2019, 52, e12551.	2.4	41
12	Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. <i>Cancer Medicine</i> , 2021, 10, 1681-1689.	1.3	39
13	Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. <i>Carcinogenesis</i> , 2010, 31, 1080-1086.	1.3	36
14	Association between VEGF Gene Polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis. <i>BioMed Research International</i> , 2018, 2018, 1-16.	0.9	15